Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Kluczowe dokumenty

Wyświetl całą dokumentację

Y0000558

Fluconazole for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Fluconazole, 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C13H12F2N6O
Numer CAS:
86386-73-4
Masa cząsteczkowa:
306.27
Numer MDL:
MFCD00274549
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329831020
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

fluconazole

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

Format

neat

temp. przechowywania

2-8°C

ciąg SMILES

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

Klucz InChI

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Flukonazol do identyfikacji szczytowej Wzorzec odniesienia EP, przeznaczony do stosowania w badaniach laboratoryjnych wyłącznie zgodnie z zaleceniami Farmakopei Europejskiej.

Działania biochem./fizjol.

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.
Fluconazole is an antifungal agent; highly selctive inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Potent inhibitor of CYP2C9. Interferes with fungal ergosterol synthesis; downregulates metallothionein gene.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
Ta strona może zawierać tekst przetłumaczony maszynowo.

produkt powiązany

Numer produktu
Opis
Cennik

PHR1160

Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material

1271700

Flukonazol, United States Pharmacopeia (USP) Reference Standard

Y0000557

Fluconazole, European Pharmacopoeia (EP) Reference Standard

Y0000574

Fluconazole impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000573

Fluconazole impurity B, European Pharmacopoeia (EP) Reference Standard

1271733

Flukonazol Związek pokrewny C, United States Pharmacopeia (USP) Reference Standard

1271722

Związek pokrewny flukonazolu B, United States Pharmacopeia (USP) Reference Standard

1271711

Związek pokrewny flukonazolu A, United States Pharmacopeia (USP) Reference Standard

PHR1651

Fluconazole Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1826

Fluconazole Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1862

Fluconazole Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2037

Fluconazole Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

BP1174

Fluconazole, British Pharmacopoeia (BP) Reference Standard

BP1175

Fluconazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2048

Fluconazole Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2046

Fluconazole Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1900

Fluconazole Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9026

1,2,4-Triazole, reference material

PHR9031

2-(2,4-Difluorophenyl)-1,2,3-propanetriol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Piktogramy

Health hazardExclamation mark
GHS08,GHS07

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H302,H360D,H362,H412

Zwroty wskazujące środki ostrożności

P202 - P260 - P263 - P273 - P301 + P312 - P308 + P313

Klasyfikacja zagrożeń

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

Kod klasy składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumenty section.

Proszę o kontakt, jeśli potrzebna jest pomoc Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Marcio Nucci et al.
PloS one, 8(3), e59373-e59373 (2013-03-26)
The epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America. We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were
A-C L Meyer et al.
Tropical medicine & international health : TM & IH, 18(4), 495-503 (2013-02-02)
To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100
Jana Bogum et al.
Journal of the American Society of Nephrology : JASN, 24(5), 744-758 (2013-04-06)
In the principal cells of the renal collecting duct, arginine vasopressin (AVP) stimulates the synthesis of cAMP, leading to signaling events that culminate in the phosphorylation of aquaporin-2 water channels and their redistribution from intracellular domains to the plasma membrane
Nicholas G Wysham et al.
Chest, 143(5), 1478-1479 (2013-05-08)
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej